Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT00700076

Organisation Name: Yale University

Overal Status: Completed

Start Date: January 22, 2008

Last Update: March 3, 2022

Lead Sponsor: Yale University

Brief Summary: Org 25935 is a new putative antipsychotic agent developed by N.V. Organon.The primary objective of this study is to investigate the effect of Org 25935 on ketamine-induced impairments in immediate recall.

Conditions:
  • Healthy


Total execution time in seconds: 0.30284786224365